



Advances in Treatment of Rare Tumors

Guest Editors:

Dr. Giorgia Mangili

Unit of Obstetrics and
Gynaecology, IRCCS San Raffaele
Scientific Institute, Via Olgettina
60, 20132 Milan, Italy

Dr. Alice Bergamini

Department of Obstetrics and
Gynecology, Ospedale San
Rafaele, 20132 Milan, Italy

Deadline for manuscript
submissions:

closed (20 September 2021)

Message from the Guest Editors

Dear Colleagues,

Gestational trophoblastic disease (GTD) is a rare entity comprising several pregnancy-related tumor subtypes, ranging from premalignant to malignant disease (commonly referred to as “gestational trophoblastic neoplasia”, GTN). Given its rarity, management and treatment can be difficult. Since the introduction of platinum-based chemotherapy, the prognosis of patients affected by GTN has dramatically improved. However, chemotherapy-resistant disease still represents a major challenge. In recent years, new, promising strategies in treatment have emerged. The aim of this Special Issue is to give an updated insight into this topic, with a particular focus on future perspectives for the treatment of GTN.

Dr. Giorgia Mangili

Dr. Alice Bergamini

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)